Jazz Pharmaceuticals (JAZZ) Q2 2024 earnings summary

Executive summary

• Achieved record Q2 2024 revenues exceeding $1.02 billion, up 7% year-over-year, driven by strong growth in neuroscience and oncology portfolios, particularly Xywav, Epidiolex, and Rylaze.

• Xywav, Epidiolex, and Zepzelca delivered double-digit year-over-year sales growth; oncology revenues exceeded $1 billion in the last twelve months.

• Net income for Q2 2024 was $168.6 million, up from $104.4 million in Q2 2023, with diluted EPS of $2.49.

• Robust pipeline with near-term catalysts, including zanidatamab, which received FDA Priority Review for 2L BTC with a PDUFA date of November 29, 2024.

• Maintained strong financial position with $2.0 billion in cash and investments as of June 30, 2024.

Financial highlights

• Q2 2024 total revenues: $1.024 billion, up 7% year-over-year, the highest quarterly revenue to date.

• Adjusted net income rose 12% year-over-year to $365 million; adjusted EPS was $5.30, up 18%.

• Cash from operations was $331 million in Q2; cash and investment balance at $2 billion as of June 30, 2024.

• Gross margin guidance unchanged at 93%; Q2 2024 GAAP gross margin was 88.6%.

• Oncology revenue guidance modestly lowered due to slower Rylaze AYA uptake, partially offset by Zepzelca strength.

Outlook and guidance

• 2024 total revenue guidance narrowed to $4.0–$4.1 billion.

• Neuroscience guidance: $2.825–$2.925 billion; Oncology guidance: $1.10–$1.15 billion.

• Adjusted net income guidance unchanged at $1.275–$1.35 billion; adjusted EPS: $19.20–$20.30.

• GAAP and non-GAAP EPS guidance increased by ~$1 per share due to lower share count.

• 2025 guidance to be provided with Q4 2024 results; Vision 2025 metrics discontinued.